- Home
- NNVC vs EDSA Comparison
NNVC vs EDSA Comparison
Compare NNVC & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNVC
- EDSA
- Stock Information
- Founded
- NNVC 2005
- EDSA 2015
- Country
- NNVC United States
- EDSA Canada
- Employees
- NNVC N/A
- EDSA N/A
- Industry
- NNVC Biotechnology: Pharmaceutical Preparations
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- NNVC Health Care
- EDSA Health Care
- Exchange
- NNVC Nasdaq
- EDSA Nasdaq
- Market Cap
- NNVC 23.1M
- EDSA 18.6M
- IPO Year
- NNVC N/A
- EDSA N/A
- Fundamental
- Price
- NNVC $1.53
- EDSA $2.16
- Analyst Decision
- NNVC
- EDSA Strong Buy
- Analyst Count
- NNVC 0
- EDSA 2
- Target Price
- NNVC N/A
- EDSA $13.00
- AVG Volume (30 Days)
- NNVC 223.4K
- EDSA 869.1K
- Earning Date
- NNVC 11-13-2025
- EDSA 12-12-2025
- Dividend Yield
- NNVC N/A
- EDSA N/A
- EPS Growth
- NNVC N/A
- EDSA N/A
- EPS
- NNVC N/A
- EDSA N/A
- Revenue
- NNVC N/A
- EDSA N/A
- Revenue This Year
- NNVC N/A
- EDSA N/A
- Revenue Next Year
- NNVC $133.33
- EDSA N/A
- P/E Ratio
- NNVC N/A
- EDSA N/A
- Revenue Growth
- NNVC N/A
- EDSA N/A
- 52 Week Low
- NNVC $0.94
- EDSA $1.55
- 52 Week High
- NNVC $1.92
- EDSA $4.49
- Technical
- Relative Strength Index (RSI)
- NNVC 56.07
- EDSA 38.19
- Support Level
- NNVC $1.40
- EDSA $2.59
- Resistance Level
- NNVC $1.63
- EDSA $2.94
- Average True Range (ATR)
- NNVC 0.09
- EDSA 0.22
- MACD
- NNVC 0.02
- EDSA -0.03
- Stochastic Oscillator
- NNVC 67.65
- EDSA 24.72
About NNVC NanoViricides Inc.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.